Healthcare Services

A key trend shaping the Acquired Immunodeficiency Syndrome (AIDS) Market Global Report 2026 Market involves the Innovative Long-Acting Injectable Therapies Revolutionizing HIV Treatment for Improved Adherence

March 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Acquired Immunodeficiency Syndrome (AIDS) Market During 2026–2030?

The market for acquired immunodeficiency syndrome (AIDS) has shown robust expansion over the past few years. Projections indicate it will expand from $33.75 billion in 2025 to $35.53 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.3%. This historical growth is linked to factors such as the widespread occurrence of HIV infections globally, enhanced awareness and screening efforts, government-backed HIV treatment programs, the introduction of early antiretroviral medications, and an increase in opportunistic infections.

The market for acquired immunodeficiency syndrome (aids) is projected to experience robust expansion over the coming years, reaching $43.28 billion by 2030, driven by a compound annual growth rate (CAGR) of 5.1%. This anticipated growth during the forecast period stems from factors such as the creation of advanced antiretroviral therapies, the broadening scope of prep and pep initiatives, progress in HIV vaccine investigations, the uptake of digital health monitoring tools, and an increase in collaborative public-private ventures for HIV management. Significant developments expected during this period involve a greater acceptance of antiretroviral therapy (ART), the increasing application of pre-exposure prophylaxis (prep) and post-exposure prophylaxis (pep), the enhancement of HIV diagnostic and surveillance frameworks, heightened emphasis on HIV vaccine research and development, and the merging of hospital and retail pharmacy services.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21076&type=smp

What Drivers Are Expected To Influence The Acquired Immunodeficiency Syndrome (AIDS) Market During The Forecast Period?

The acquired immunodeficiency syndrome (AIDS) market is anticipated to expand due to the increasing incidence of HIV infections. HIV infections characterize a condition caused by the human immunodeficiency virus (HIV), which targets the immune system, consequently diminishing the body’s capacity to combat infections and diseases. The escalating rates of HIV infections are attributed to various factors including unprotected sexual contact with an infected individual, sharing needles or syringes, receiving contaminated blood products, having multiple sexual partners, and a weakened immune system or pre-existing sexually transmitted infections. Managing acquired immunodeficiency syndrome (AIDS) supports HIV-infected patients by promoting early diagnosis, broadening access to effective antiretroviral therapies, strengthening prevention strategies, and improving healthcare systems, all of which contribute to better control over the virus’s dissemination. For instance, in November 2024, data published by the European Centre for Disease Prevention and Control (ECDC), a Sweden-based European Union agency, revealed that a total of 112,883 HIV diagnoses were reported in 2023 across 47 out of 53 countries in the region, with 24,731 cases specifically recorded in the European Union/European Economic Area (EU/EEA). The overall crude rate for HIV diagnoses reached 12.7 per 100,000 population, representing a 2.4% increase when compared to the 12.4 per 100,000 rate observed in 2022. Thus, the rise in HIV infections is propelling the acquired immunodeficiency syndrome (AIDS) market.

How Are The Various Segments Of The Acquired Immunodeficiency Syndrome (AIDS) Market Categorized?

The acquired immunodeficiency syndrome (aids) market covered in this report is segmented –

1) By Type: Human Immunodeficiency Virus 1, Human Immunodeficiency Virus 2

2) By Drug Type: Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Fusion Inhibitors, CCR5 Anatagonists And Post-Attachment Inhibitors, Protease Inhibitors, Integrase Inhibitors, Pre-Exposure Prophylaxis And Post-Exposure Prophylaxis

3) By Route Of Administration: Oral, Parenteral

4) By Application: Hospital Pharmacy, Retail Pharmacy, Other Applications

5) By Distribution Channel: Offline, Online

Subsegments:

1) By Human Immunodeficiency Virus 1 (HIV-1): Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), HIV-1 Diagnostic Tests, HIV-1 Vaccine Development, HIV-1 Opportunistic Infection Management

2) By Human Immunodeficiency Virus 2 (HIV-2): Antiretroviral Therapy (ART) For HIV-2, HIV-2 Diagnostic Tests, HIV-2 Surveillance And Epidemiology, HIV-2 Vaccine Research, Management Of HIV-2 Co-Infections

What Trends Are Affecting The Expansion Of The Acquired Immunodeficiency Syndrome (AIDS) Market?

Leading companies within the acquired immunodeficiency syndrome (AIDS) market are prioritizing the development of innovative therapies, such as long-acting injectables. These advancements aim to improve patient compliance, reduce the frequency of administration, and offer a more convenient alternative to daily oral antiretroviral treatments. Long-acting injectables are medications given via injection, designed to slowly release their active ingredients over an extended period, thus allowing for less frequent dosing compared to traditional oral medications. For instance, in January 2025, GSK plc, a UK-based pharmaceutical company, announced that the European Commission had approved its long-acting injectable treatment, Vocabria (cabotegravir) plus Rekambys (rilpivirine). This treatment is approved for use in adolescents aged 12 years and older who are living with HIV. It is administered via intramuscular injection, typically every one or two months, depending on the specific treatment plan. The prolonged action of these injections may enhance adherence rates among adolescents who face challenges with daily pill regimens.

Which Major Firms Influence Developments In The Acquired Immunodeficiency Syndrome (AIDS) Market?

Major companies operating in the acquired immunodeficiency syndrome (aids) market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi SA, Bristol-Myers Squibb Company, Abbott, GSK plc, Takeda Pharmaceuticals, Gilead Sciences, Viatris Inc., Teva Pharmaceuticals, Aurobindo Pharma, Cipla Ltd, Shionogi and Co., Dr. Reddy’s Laboratories, Lupin, Hetero Drugs Limited, Glenmark Pharmaceuticals Limited, ViiV Healthcare

Read the full acquired immunodeficiency syndrome (aids) market report here:

https://www.thebusinessresearchcompany.com/report/acquired-immunodeficiency-syndrome-aids-global-market-report

Which Region Is Forecast To Lead The Acquired Immunodeficiency Syndrome (AIDS) Market In Terms Of Market Size?

North America was the largest region in the acquired immunodeficiency syndrome (AIDS) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired immunodeficiency syndrome (aids) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Acquired Immunodeficiency Syndrome (AIDS) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21076&type=smp

Browse Through More Reports Similar to the Global Acquired Immunodeficiency Syndrome (AIDS) Market 2026, By The Business Research Company

Acne Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/acne-drugs-global-market-report

walking aids global market report

https://www.thebusinessresearchcompany.com/report/walking-aids-global-market-report

immunoassay global market report

https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795